BioCentury | Dec 13, 2019
Preclinical News

Dec. 12 Preclinical Quick Takes: POC for Aptose blood cancer candidate, plus Penn-Acorn AI, Neurimmune-Biogen and Syndax

...In a pair of posters at the American Society of Hematology (ASH) meeting in Orlando, Aptose Biosciences Inc....
...Interleukin-6; MLL - Myeloid/lymphoid or mixed-lineage leukemia BioCentury Staff Syndax Pharmaceuticals Inc. Biogen Inc. University of Pennsylvania Medidata Solutions Inc. Aptose Biosciences Inc. University...
BioCentury | Dec 6, 2019
Company News

Management tracks: Cancer therapy pioneer Desmond-Hellmann leaving Gates Foundation; plus CStone, Janssen, Akcea, insitro and more

...company hired Marott in July, he was CFO of Veloxis Pharmaceuticals A/S (CSE:VELO). Cancer company Aptose Biosciences Inc....
...affairs at Indivior plc (LSE:INDV). BioCentury Staff Akcea Therapeutics Inc. insitro Inc. RAPT Therapeutics Inc. Polaris Partners Innovative Cellular Therapeutics Co. Ltd. Aptose Biosciences Inc. Circassia...
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...plc (NASDAQ:ORTX) 6/5/19 $128.3 $1,351.9 $1,327.2 -2% XBiotech Inc. (NASDAQ:XBIT) 5/31/19 $40.0 $337.9 $310.3 -8% Aptose Biosciences Inc....
BioCentury | Jul 13, 2018
Clinical News

FDA lifts hold on Aptose blood cancer candidate

...APTO-253 is a small molecule optimized to increase expression of Kruppel-like factor 4 (KLF4; EZF). Aptose Biosciences Inc....
...dose (MTD) and dose-limiting toxicities (DLTs); pharmacokinetics Status: Clinical hold lifted Milestone: NA Allison Johnson APTO-253, lor-253, lt-253 Aptose Biosciences Inc. Kruppel-like...
BioCentury | Feb 3, 2017
Clinical News

APTO-253: Development delayed

...APTO-253 until the company encountered an additional manufacturing setback (see BioCentury, Oct. 24, 2016 ). Aptose Biosciences Inc....
...Endpoint: Maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs); pharmacokinetics Status: Development delayed Milestone: NA Julian Zhu APTO-253 Aptose Biosciences Inc. Kruppel-like...
BioCentury | Oct 24, 2016
Clinical News

APTO-253: Phase Ib hold

...report of an operational difficulty with an IV infusion pump (see BioCentury, Dec. 14, 2015). Aptose Biosciences Inc....
BioCentury | Sep 19, 2016
Clinical News

APTO-253: Phase Ib hold

...the trial following concerns regarding documentation records of manufacturing procedures (see BioCentury. Dec. 14, 2015). Aptose Biosciences Inc....
BioCentury | Jul 21, 2016
Distillery Therapeutics

Therapeutics: Interleukin-25 (IL-25; IL-17E)

...steps could include identifying and testing promoters of IL-25 expression in animal models of CDI. Aptose Biosciences Inc....
BioCentury | Jun 13, 2016
Company News

CrystalGenomics, Aptose Biosciences deal

...FLT3 ; CD135 ) and Aurora kinases . CrystalGenomics Inc. (KOSDAQ:083790), Seongnam, South Korea Aptose Biosciences Inc....
BioCentury | Jun 9, 2016
Company News

Aptose, CrystalGenomics in deal for multi-kinase inhibitor

...CrystalGenomics Inc. (KOSDAQ:083790) granted Aptose Biosciences Inc. (TSX:APS; NASDAQ:APTO) an exclusive option to license rights to CG026806 outside...
Items per page:
1 - 10 of 243
BioCentury | Dec 13, 2019
Preclinical News

Dec. 12 Preclinical Quick Takes: POC for Aptose blood cancer candidate, plus Penn-Acorn AI, Neurimmune-Biogen and Syndax

...In a pair of posters at the American Society of Hematology (ASH) meeting in Orlando, Aptose Biosciences Inc....
...Interleukin-6; MLL - Myeloid/lymphoid or mixed-lineage leukemia BioCentury Staff Syndax Pharmaceuticals Inc. Biogen Inc. University of Pennsylvania Medidata Solutions Inc. Aptose Biosciences Inc. University...
BioCentury | Dec 6, 2019
Company News

Management tracks: Cancer therapy pioneer Desmond-Hellmann leaving Gates Foundation; plus CStone, Janssen, Akcea, insitro and more

...company hired Marott in July, he was CFO of Veloxis Pharmaceuticals A/S (CSE:VELO). Cancer company Aptose Biosciences Inc....
...affairs at Indivior plc (LSE:INDV). BioCentury Staff Akcea Therapeutics Inc. insitro Inc. RAPT Therapeutics Inc. Polaris Partners Innovative Cellular Therapeutics Co. Ltd. Aptose Biosciences Inc. Circassia...
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...plc (NASDAQ:ORTX) 6/5/19 $128.3 $1,351.9 $1,327.2 -2% XBiotech Inc. (NASDAQ:XBIT) 5/31/19 $40.0 $337.9 $310.3 -8% Aptose Biosciences Inc....
BioCentury | Jul 13, 2018
Clinical News

FDA lifts hold on Aptose blood cancer candidate

...APTO-253 is a small molecule optimized to increase expression of Kruppel-like factor 4 (KLF4; EZF). Aptose Biosciences Inc....
...dose (MTD) and dose-limiting toxicities (DLTs); pharmacokinetics Status: Clinical hold lifted Milestone: NA Allison Johnson APTO-253, lor-253, lt-253 Aptose Biosciences Inc. Kruppel-like...
BioCentury | Feb 3, 2017
Clinical News

APTO-253: Development delayed

...APTO-253 until the company encountered an additional manufacturing setback (see BioCentury, Oct. 24, 2016 ). Aptose Biosciences Inc....
...Endpoint: Maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs); pharmacokinetics Status: Development delayed Milestone: NA Julian Zhu APTO-253 Aptose Biosciences Inc. Kruppel-like...
BioCentury | Oct 24, 2016
Clinical News

APTO-253: Phase Ib hold

...report of an operational difficulty with an IV infusion pump (see BioCentury, Dec. 14, 2015). Aptose Biosciences Inc....
BioCentury | Sep 19, 2016
Clinical News

APTO-253: Phase Ib hold

...the trial following concerns regarding documentation records of manufacturing procedures (see BioCentury. Dec. 14, 2015). Aptose Biosciences Inc....
BioCentury | Jul 21, 2016
Distillery Therapeutics

Therapeutics: Interleukin-25 (IL-25; IL-17E)

...steps could include identifying and testing promoters of IL-25 expression in animal models of CDI. Aptose Biosciences Inc....
BioCentury | Jun 13, 2016
Company News

CrystalGenomics, Aptose Biosciences deal

...FLT3 ; CD135 ) and Aurora kinases . CrystalGenomics Inc. (KOSDAQ:083790), Seongnam, South Korea Aptose Biosciences Inc....
BioCentury | Jun 9, 2016
Company News

Aptose, CrystalGenomics in deal for multi-kinase inhibitor

...CrystalGenomics Inc. (KOSDAQ:083790) granted Aptose Biosciences Inc. (TSX:APS; NASDAQ:APTO) an exclusive option to license rights to CG026806 outside...
Items per page:
1 - 10 of 243